The startup develops set-point vaccines that utilize synthetic non-biological components to prime immune cells for targeting and eliminating pathogen-infected cells. These vaccines aim to prevent severe manifestations of viral and bacterial diseases, including dengue fever, Zika, Ebola, and pandemic flu.
Funding
$53.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional vaccines often struggle to provide broad and long-lasting immunity against rapidly mutating viruses and intracellular bacteria, requiring frequent boosters and exhibiting limited effectiveness against new variants. Conventional vaccine administration methods can also pose logistical challenges, particularly in developing countries, due to cold chain requirements and the need for trained healthcare professionals.
Solution
Gylden Pharma is developing synthetic T cell-priming vaccines and immunotherapies designed to elicit broad and long-lasting cellular immune responses against infectious diseases and cancer. Gylden's vaccines utilize a fully synthetic composition, eliminating the need for live or attenuated pathogens, and target conserved regions of pathogens to overcome mutational escape. The company's core technology combines immunoproteomics, multi-omic technologies, a nanocluster delivery system, and microneedle array patch (MAP) technology to deliver targeted synthetic peptides to the skin-resident immune system, activating T cells and generating a robust, durable immune response. This approach mimics the body's natural cellular immune response, enabling rapid elimination of infected cells upon subsequent pathogen encounter.
Target Audience
The primary target audience includes individuals at risk of infectious diseases, public health organizations seeking to improve pandemic preparedness, and patients with cancer who may benefit from novel immunotherapies.
Features
- 100% synthetic vaccines, eliminating the risks associated with live or attenuated pathogens
- T cell-priming approach designed to induce long-lasting cellular immunity, potentially for decades
- Targets conserved pathogen recognition elements to provide broad protection against multiple strains and variants
- Nanoparticle delivery system for efficient delivery of synthetic peptides to the skin-resident immune system
- Microneedle array patch (MAP) technology for convenient, intradermal administration, reducing the need for trained healthcare providers
- Room temperature stability, eliminating cold chain requirements and enabling easy transportation to remote areas
- In-house GMP nanomedicine manufacturing capabilities
- Pipeline includes candidates for Betacoronavirus, Dengue Fever, Universal Influenza, and intracellular bacterial infectious diseases